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’ INTRODUCTION
Human symbiotic gut microorganisms perform a variety of
useful functions via interactive microbialhost co-metabolism
and signaling, which are closely involved with digestion of un-
utilized energy substrates to generate biologically important meta-
bolites such as short-chain fatty acids (SCFAs), biotin and
vitamin K, stimulate cell growth, and also repress the growth
of harmful microorganisms, thereby defending against some
diseases.13 We have recently proposed a therapeutic strategy of
manipulating the gut microbiome so that the dysregulation of the
microbialmammalian co-metabolism associated with a pathological
state can be reversed.4 By using this strategy, the gut microbiotic
environment could therefore be a new source of drug targets for
the treatment of metabolic disorders, various conditions in the
gastrointestinal (GI) tract and also neurological disorders.5
The variation in the GI metabolism is related directly to the
activities of various microorganisms that coexist in the gut. With
the recent advances in metagenomics6 based on 16S rRNA gene
sequence methods,79 the direct correlation of global metabolic
footprints with gutmicrobiome becomes technically feasible with
an aim to decipher the hostmicrobe relationships and to
discover novel molecular targets in the microbialmammalian
metabolic axis. Our recent study of human gut microbiota using
metabolic profiling coupled with the metagenomic sequencing
provided a basis for understanding the “microbialmammalian
metabolic axis”, which led to the concept of “functional meta-
genomics”, defined as “the characterization of key functional
members of the microbiome that most influence host metabo-
lism and hence health”.10
Given the integral nature of a specific gut microbiome and
metabolome, any differences in the microbial communities could
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result in significant alterations in the extracellular metabolome
(metabolic footprints), which may account for important find-
ings commonly encountered in pathology, toxicology or drug
metabolism studies. Metabonomics (or metabolomics), an array
of analytical techniques including high-resolution nuclear mag-
netic resonance (NMR) spectroscopy11 and chromatography
mass spectrometry (MS),12,13 enables comprehensive character-
ization of the metabolic footprints of mammalian hosts that can
be correlated to the microbial community in the intestinal
tract.14,15 Recent studies by Nicholson et al.1618 demonstrate
that the metabolic variations in GI compartments such as
duodenum, jejunum, and ileum, mammalian tissues from kidney
and liver, and biofluids such as blood and urine are directly
related to the activities of various microorganisms that coexist in
the gut.
Here, we report a profiling study of urinary and fecal meta-
bolites in Wistar rats exposed to a broad spectrum β-lactam
antibiotic, Imipenem/cilastatin sodium, in a specific pathogen-
free (SPF) environment, using both gas chromatographymass
spectrometry (GCMS) and liquid chromatographymass
spectrumetry (LCMS). Urine and feces samples were collected
at day 0 (predose), days 14 during antibiotic treatment, and
days 5, 8, 12, and 18 of recovery period. The aim of this study is to
provide important baseline information of a complete spectrum
of metabolites produced from the microbialmammalian co-me-
tabolism, to improve our understanding of the “functional meta-
genome” as well as molecular mechanisms underlying multilevel
hostmicrobe interactions.
’MATERIALS AND METHODS
Chemicals
Imipenem/cilastatin sodium (with equal quantities, trade named
Tienam), a broad spectrum β-lactam antibiotic, was purchased
fromChinaNational Pharmaceutical GroupCorporation (Shanghai,
China) and authorized for experimental use by School of Pharmacy,
Shanghai JiaoTongUniversity (Shanghai, China). It was prepared in
ultrapure water (Milli-Q system, Millipore, Billerica, MA) at a
concentration of 5 mg/mL. Methanol, acetonitrile, formic acid,
chloroform and pyridine with HPLC grade were purchased from
Merck Chemicals (Darmstadt, Germany). p-Chlorophenylala-
nine, urease (30 U, Type C), BSTFA (1% TMCS), methoxya-
mine, leucine-enkephalin and all of the mammalian standards
used for compound annotation and mix standards were obtained
from Sigma-Aldrich (St. Louis, MO).
Animal Handling and Sample Collection
The animal study was performed at the Center for Laboratory
Animals, Shanghai Jiao TongUniversity, Shanghai, China. A total
of 12 male Wistar rats (4 weeks old; 7888 g) were purchased
from Shanghai Laboratory Animal Co, Ltd. (SLAC, Shanghai,
China). All rats were housed in a specific-pathogen-free (SPF)
environment, under a controlled condition of 12 h light/12 h
dark cycle at 2022 C and 45 ( 5% humidity, with free access
to chow and water. After one-week accommodation in metabolic
cages, the rats were randomly divided into 2 groups: antibiotic-
perturbed group (n = 6), dosed with antibiotic Imipenem/
cilastatin sodium at a daily dose of 50 mg/kg of body weight
from day 1 to day 4 and control group (n = 6), which received the
same volume of water, antibiotic vehicle, from day 1 to day 4.
After antibiotic perturbation, all rats were housed in a controlled
environment for another 14 days as a recovery period. The
volume of water and chow consumed and body weight of each rat
were recorded carefully every day. Daily 18-h (20:00 p.m.14:00
p.m. on the next day) urine and feces (19:00 p.m.) samples were
collected throughout the experiment and frozen (80 C)
stored until analysis. Samples were collected at day 0
(predose), days 14 during antibiotic treatment, and days 5, 8,
12, and 18 of recovery period for metabonomic analysis.
Sample Preparation
Urine samples were prepared using the protocol established
by our lab,19,20 and feces samples were extracted according to that
described in published papers21 with minor modification.
Metabonomic Profiling with LCMS and GCMS
A Waters ACQUITY ultra performance liquid chromatogra-
phy (UPLC) system equipped with a binary solvent delivery
manager and a sample manager (Waters Corporation, Milford,
MA), coupled to a tandem quadrupole-time-of-flight (Q-TOF)
mass spectrometry equipped with an electrospray interface
(Waters Corporation, Milford, MA) was used as a LCMS
platform. An Agilent 6890N gas chromatography coupled with a
Pegasus HT time-of-flight (TOF) mass spectrometry (Leco
Corporation, St. Joseph, MI) was used as the GCMS platform.
The samples were run in the order of “control-antibiotic-
control”, alternately, to minimize systematic analytical devia-
tions. Mixed standards sample as quality control was injected
every 10 injections.
Spectral Data Analysis
The MS data of urine and feces samples collected at different
time points were analyzed to identify potential discriminate
variables. For LCMS, the raw data were analyzed by the
MarkerLynx applicationsmanager version 4.1 (Waters, Manchester,
U.K.). The parameters used were set as follows: initial retention
time = 0.00 min, final retention time = 9.5 min (as the rest time
was for column equilibration), mass tolerance (Da) = 0.02, peak
width at 5% height was auto, peak to peak baseline noise was
auto, intensity threshold = 50, mass window = 0.02, retention
time window = 0.2 min, and noise elimination level = 6. The
resulting matrix contained arbitrarily assigned peak index
(retention time (Rt)m/z pairs), sample names and peak
intensity. After data processing, a list of the intensities of the
peaks detected was generated for the first sample, using Rt and
m/z data pairs as the identifier of each peak. The acquired MS
files from GCMS analysis were exported in NetCDF format by
ChromaTOF software (v3.30, Leco Co., Los Angeles, CA). CDF
files were extracted using custom scripts (revised Matlab toolbox
HDA, developed by Par Jonsson, et al.22) in the MATLAB 7.1
(The MathWorks, Inc., Natick, MA) for data pretreatment
procedures such as baseline correction, denoising, smoothing,
and alignment; time-window splitting; and peak feature extrac-
tion (based on multivariate curve resolution algorithm). The
resulting three dimension data set included sample information,
peak retention time and peak intensities.
Compound Identification
Compound identification was performed using our in-house
library containing ∼800 mammalian metabolite standards. For
LCMS generated data, identification was performed by com-
paring with the accurate mass and Rt of reference standards in
our in-house library and the accurate mass of compounds
obtained from the web-based resources such as the Human
Metabolome Database (http://www.hmdb.ca/) and METLIN
(http://metlin.scripps.edu). For GCMS generated data,
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identification was processed by comparing with the mass frag-
ments and Rt of reference standards in our in-house library or
mass fragments with NIST 05 Standard mass spectral databases
in NISTMS search 2.0 (NIST, Gaithersburg, MD) software with
a similarity of more than 70%.
Statistical Analysis
Internal standards and any known artificial peaks, such as
peaks caused by noise, column bleed and BSTFA derivatization
procedure, were removed from the data sets obtained in above
Section (Spectral Data Analysis). Urine data were normalized to
the total intensity, while feces data did not need to be normalized
since the extraction solvent adding in feces depended on the
weight of feces, keeping the same feces concentration of different
weights of samples. Data were then mean centered and unit
variance scaled in a columnwise manner in the Simca-P 12.0
Software package (Umetrics, Umea, Sweden). PLS-DA was car-
ried out to get the three-dimensional discriminations and trajec-
tories by score parameters after combining the data from
two different instruments of the same sample. All the metabolites
identified were processed at a univariate analysis using a
two-tailed unpaired t test with the critical p value set to 0.05.
The fold changes were the intensity mean value ratio of antibiotic
group to control group in the corresponding day. Heat-maps
were created to visualize the metabolites derived from gut
microbialmammalian co-metabolism and t test was carried
out in MATLAB 7.1 (The MathWorks, Inc., Natick, MA).
Additionally, KEGG Global Pathway Map was constructed in
Cytoscape 2.8.0.23
’RESULTS
Effect of Antibiotic Intervention in Urine and Feces
Experimental rats displayed diarrhea throughout the 4 day
antibiotic treatment period. The diarrhea incidence was reduced
after the first day of antibiotic withdrawal and stopped 6 days
before the end of experiment. Themetabolic alteration caused by
the microbial alterations after antibiotic treatment was substan-
tial. The complex metabolic effects and dynamic changes of
microbial manipulation were visualized by comparing the anti-
biotic treated rats to nonantibiotic control rats. The time-
dependent metabolic “footprints” in urine and feces of experi-
mental rats resulting from antibiotic exposure are illustrated in
Figure 1 across the 4-day treatment period and the 14-day
recovery period with the criterion described by Holmes et al.24
The effect of Imipenem on the gut microbiota was profound and
Figure 1. Alteration of metabolome shown by trajectories and PLS-DA plots. Scores plots of PLS-DA are derived from (A) urinary and (B) fecal
metabonomic (combined GCMS and LCMS) data for the control group (blue) and the antibiotic group (red) across the time course of predose
(day 0), antibiotic treatment (days 14) and recovery period (days 518). Each dot in the plots represents mean value of the scores from the first and
second principal components at a time point. The circle and dot denote the starting point (predose, day 0) and the end point (day 18), respectively.
PLS-DA scores plots of (C) urinary and (D) fecal metabolic profiles show similar time-dependent changes of the antibiotic group at different
time points.
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rapid, with most significant changes in metabolic profile from the
day prior to the antibiotic treatment to day 1. The trajectories
show that the urinary and fecal metabolic changes (Figure 1)
underwent a significant shift from day 0 to day 1, continued to
“drift away” from day 1 to day 5, and gradually recovered with a
steady pattern approaching the control (nonantibiotic) group.
The metabolic trajectories generated from LCMS or GCMS
based metabonomic data (Supplementary Figure 1, Supporting
Information) are similar to that of combined data set shown in
Figure 1. PLS-DA scores plots ((C) R2X = 0.36, R2Y = 0.545,
Q2Y = 0.37; (D) R2X = 0.744, R2Y = 0.969, Q2Y = 0.616) showed
the dynamic change in the antibiotic group within the selected
days. A clear differentiation of the antibiotic perturbation can be
observed that the points of each animal in the first, third and fifth
day clustered, respectively, far from the predose points. Those
points representing day 12 and day 18 were close to the predose
points, showing a normalization of metabolic profiles after day
12. The trajectories of both urinary and fecal metabolic profiles
in Figure 1 suggest that the experimental rats in the antibiotic
treatment group were able to restore their microbial commu-
nity composition after a 2-week recovery period. This is also
evidenced by the heat-maps of the urinary and fecal metabolites
showing metabolic fluctuations normalized from day 818 in
Figure 2.
Altered Metabolite Patterns in Urine and Feces
To characterize the metabolic perturbation in response to
antibiotic intervention in urine and feces, representative
Figure 2. Heat-maps of representative urinary and fecal metabolites involved in gut microbialmammalian co-metabolism. Heat-maps show the time-
dependent fluctuations (red = increased concentration, blue = decreased concentration) of (left) urinary and (right) fecal metabolites as a result of
microbial perturbation. Each cell in the heat-maps represents the fold change of a particular metabolite, which is the ratio of the concentration in the
antibiotic group to that in the control group.
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Table 1. Representative Urinary and Fecal Metabolites Derived from Gut MicrobialMammalian Co-metabolisma
metabolic pathway urinary metabolites fecal metabolites
Tryptophan Metabolism TryptophanLC3 TryptophanLC1
5-HydroxytryptopholLC3 5-HydroxytryptopholLC3
TryptamineLC3 TryptamineLC3
2-IndoleacetaldehydeLC3 2-IndoleacetaldehydeLC3
2-Indolecarboxylic acidLC3 2-Indolecarboxylic acidLC3
6-Hydroxymelatonin sulfateLC1 6-Hydroxymelatonin sulfateLC1
TryptophanolLC3 Nicotinic acidLC1
Indoleacetic acidLC1
Indolelactic acidLC3
IndoleLC3
N-MethyltryptamineLC3
Kynurenic acidGC1
Indoxyl sulfateGC1
HydroxykynurenineLC1
NicotinamideGC1
Tyrosine and Phenylalanine Metabolism TyrosineLC3 TyrosineLC1
2-PhenylacetamideLC3 2-PhenylacetamideLC3
PhenylethanolamineLC3 PhenylethanolamineLC3
PhenylacetaldehydeLC3 PhenylacetaldehydeLC3
Phenylacetic acidLC3 Phenylacetic acidLC3
p-Hydroxyphenylacetic acidGC1 p-Hydroxyphenylacetic acidGC1
m-Hydroxyphenylacetic acidGC1 m-Hydroxyphenylacetic acidGC1
p-Hydrocinnamic acidGC2 p-Hydrocinnamic acidGC2
Shikimic acidLC1 PhenylalanineGC1
PhenolGC1 TyramineGC1
ThyronineLC1 DopaLC1
p-Hydroxybenzoic acidGC1 Hydrocaffeic acidGC2
Hippuric acidGC1 Hydroxydopamine LC1
MelaninLC3 Epinephrine sulfateLC3
DopamineLC1
Homovanillic acidGC1
NormetanephrineLC1
Organic Acids Metabolism Butyric acidGC1 Butyric acidLC3
Isobutyric acidLC3 Isobutyric acidGC2
Lactic acidGC1 Lactic acidGC1
2-Methylbutyric acidGC1 3-Hydroxybutyric acidGC1
Hydroxyisobutyric acidGC1 4-Aminobutyric acidGC2
Propionic acidGC3 Caprylic acidGC2
Myristic acidGC1
Palmitic acidGC1
Suberic acidGC1
Oligopeptides Aspartyl-glutamic acidLC3
Aspartyl-leucineLC3
Aspartyl-serineLC3
Leucyl-prolineLC3
Phenylalanyl-hydroxyprolineLC3
Prolyl-glycineLC3
Carbohydrate Metabolism N-acetyl-glucosamineGC2 N-acetyl-glucosamineLC1
GlucoseGC2 GlucoseGC2
Glucose 6-phosphateLC1 Glucose 6-phosphateLC1
Myo-inositolGC2 Myo-inositolGC1
Threonic acidGC1 Threonic acidLC3
ArabitolLC1 ArabitolGC1
ArabinoseLC1 ArabinoseLC1
XylitolGC1 XylitolGC1
XyloseGC1 XyloseLC1
RiboseGC1 RiboseGC1
FructoseGC1 FucoseGC1
RhamnoseGC1
Gluconic acidGC2
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Table 1. Continued
metabolic pathway urinary metabolites fecal metabolites
Purine and Pyrimidine Metabolism HypoxanthineLC1 HypoxanthineLC1
AllantoinGC1 AllantoinGC2
MethylguanineLC1 MethylguanineLC1
ThymineLC1 ThymineLC1
DeoxycytidineLC1 DeoxycytidineGC2
CytosineGC1 CytosineLC1
UracilGC1 UracilLC1
β-AlanineGC1 β-AlanineGC1
PurineLC1 PhosphoribosylformylglycineamidineLC3
5-AminoimidazoleLC3 InosineLC3
AdenosineLC1 dIDPLC3
GuanosineLC1 XanthineLC1
Methylmalonic acidGC1 XanthosineLC3
DeoxyuridineLC1 Adenosine 50-monophosphateLC1
Malonic acidGC1 AdenineLC1
Orotic acidGC1 CytidineLC1
Carbamoyl aspartateLC3
Histidine Metabolism Urocanic acidLC3 Urocanic acidLC3
L-MethylhistidineLC1 HistidineLC1
4-Imidazolone-5-propionic acidLC3
Imidazole-4-acetaldehydeLC3
Imidazoleacetic acidLC3
Methylimidazoleacetic acidLC3
Cysteine and Methionine Metabolism CysteineGC1 CysteineGC1
2-Oxo-4-methylthiobutyric acidLC3 2-Oxo-4-methylthiobutyric acidLC3
HypotaurineGC1 HypotaurineLC1
5-GlutamyltaurineLC3 5-GlutamyltaurineLC3
O-PhosphoserineLC1
Pyroglutamic acidLC1
HomocysteineLC1
MethionineLC1
UreaGC1
Valine, Leucine and Isoleucine Metabolism IsoleucineGC1 IsoleucineLC1
LeucineGC1 ValineGC1
KetoleucineGC2
Lysine Metabolism LysineLC1 LysineGC1
GlycineLC1 GlycineGC1
Glutaric acidGC1 Glutaric acidGC1
CadaverineGC1 CadaverineGC2
2,6-Diaminopimelic acidLC3
MethyllysineLC3
SaccharopineLC3
Pipecolinic acidGC2
Arginine and Proline Metabolism 5-Aminopentanoic acidGC2 5-Aminopentanoic acidGC2
GlutamineGC1 GlutamineLC1
OrnithineGC1 OrnithineLC1
CreatinineGC1 CreatinineLC1
ProlineLC1 ProlineGC1
SarcosineGC2
Glutamic acidLC1
CitrullineLC1
Guanidineacetic acidLC1
CreatineGC1
PutrescineGC2
4-HydroxyprolineLC1
TCA Cycle Pyruvic acidGC1 Pyruvic acidGC1
Oxoglutaric acidGC2 Oxoglutaric acidGC2
Citric acidLC1 Itaconic acidLC1
cis-Aconitic acidGC2 Succinic acidLC1
Fumaric acidGC2
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metabolites that were most significantly altered in urine and feces
in at least one day during the course of antibiotic treatment and
recovery are listed in Table 1 with p values of two-tailed un-
paired t test less than 0.05. A complete list of differential
metabolites containing 202 urinary metabolites and 223 fecal
metabolites is provided in Supplementary Table 1 and 2 with
information of p value and fold change (FC) of mean intensity
every day. Fifty representativemetabolites were used to construct
a heat-map, visualizing the time-dependent fluctuation of gut
microbe-related metabolites (Figure 2). The heat-maps gener-
ated from a complete list of differential metabolites of urine and
feces are provided in Supplementary Figure 2. The heat-maps
visualized that the fluctuations in most of the metabolites in urine
and feces samples were substantial at the first several days and
attenuated in the recovery stage.
Altered Distribution of Metabolites Related to Gut Microbiota
Table 1 lists a number of aromatic substances, such as ben-
zene and indole-containing substances, showing significant fluc-
tuations (with large fold changes) both in urine and feces. The
benzene-containing substances include p-hydroxyphenylacetic
acid, m-hydrophenylacetic acid, hydroxycinnamic acid, phenyl-
valeric acid, and p-aminobenzoic acid. Hippuric acid in urine was
of significantly lower level from day 1 to day 5 in the antibiotic
group compared with the control group. Most of indole-contain-
ing substances including indoxyl sulfate, indoleacetic acid, in-
dolecarboxylic acid, indoleacetaldehyde were decreased after
antibiotic exposure. The two pie charts in Figure 3 illustrate
the categories of the altered metabolites in urine and feces
samples of antibiotic-perturbed rats. Tryptophan metabolism
appeared to be significantly altered in the antibiotic group both
in urine and feces. Tryptophan and tryptamine increased signifi-
cantly in feces with antibiotic treatment as shown in Figure 4.
Methyltryptamine and hydroxytryptophol were also increased
while tryptophan decreased in urine. Many SCFAs were detected
with lower levels both in urine and feces. SCFAs in feces were
down-regulated to amuch greater extent than those in urine. Several
oligopeptides especially dipeptides and tripeptides significantly
increased in urine. Urobilin was significantly depleted both in
urine and feces.
’DISCUSSION
A number of different antibiotics have thus far been applied to
the investigations of antibiotic perturbed gut microbiota, with
a different effect of microbial perturbation.2527 Imipenem is a
β-lactam antibiotic with an extremely broad spectrum of activity
against aerobic and anaerobic gram positive as well as gram negative
bacteria, and therefore, was selected in our study to rapidly and
completely remove the microbes from the GI tract. The anti-
biotic agent remains stable in the presence of β-lactamase (both
penicillinase and cephalosporinase) and is a strong inhibitor of
β-lactamases from gram-negative bacteria that are resistant to
most β-lactam antibiotics.28 On the basis of its poor systemic
bioavailability, Imipenem’s direct impact is on the gut micro-
biota, instead of host metabolic pathways. A study on the analysis
of urine samples collected from cynomolgus monkey dosed with
imipenem revealed a significant increase of β-hydroxybutyrate
and ketone bodies, indicating a disruption of energy metabolism
resulting from the suppression of gut microflora.29 Imipenem,
Table 1. Continued
metabolic pathway urinary metabolites fecal metabolites
Others GlycylprolylhydroxyprolineLC3 GlycylprolylhydroxyprolineLC3
Citramalic acidGC1 Citramalic acidLC1
Aminomalonic acidGC2 Aminomalonic acidLC3
Argininic acidLC3 Argininic acidLC3
Hydroxyglutaric acidLC3 Hydroxyglutaric acidGC2
D-1-Piperideine-2-carboxylic acidLC3 D-1-Piperideine-2-carboxylic acidLC3
DihydrodaidzeinLC3 DihydrodaidzeinLC3
UrobilinLC3 UrobilinLC3
N-AcetylcadaverineLC3 N-AcetylcadaverineLC3
N-MethylformamideLC3 N-MethylformamideLC3
Ophthalmic acidLC3 Ophthalmic acidLC3
Phenyllactic acidLC1 Phenyllactic acidGC1
Salicyluric acidLC3 Salicyluric acidLC3
S-SuccinyldihydrolipoamideLC3 S-SuccinyldihydrolipoamideLC3
4-Hydroxycyclohexylcarboxylic acidLC3 4-Hydroxycyclohexylcarboxylic acidGC2
PhenylalanylhydroxyprolineLC3 PhenylalanylhydroxyprolineLC3
3-(3-Hydroxyphenyl)propionic acidGC2 3-(3-Hydroxyphenyl) propionic acidGC2
CarnitineLC1
a LC, identified from LCMS data (exact mass); GC, identified from GC-MS data; 1, annotated with reference standards; 2, annotated with National
Institute of Standards and Technology (NIST) database; 3, annotated with Human Metabolome Database (HMDB).
Figure 3. Classification of urinary and fecal metabolites derived from
gut microbialmammalian co-metabolism as pie charts shown.
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cilastatin and their metabolites were rapidly excreted and, thus,
not detected by mass spectrometry analysis from the samples
collected at the time points of the experiment.
The globalmetabolic effects and dynamic changes of microbial
composition in the antibiotic treated rats can be visualized from
trajectories, PLS-DA scores plots and heat-maps in Figures 1 and 2.
The trajectories of urinary and fecal metabolome displayed the
dynamic changes in the antibiotic group during 19 days of ex-
periment along the second principal component, and showed
age-related physiological changes along the first pricinpal com-
ponent in both groups. These systemic visualization plots suggest
that experimental rats after a 4-day antibiotic treatment were able
to regain the gut metabolic and ecological balance within a
2-week recovery period. Since the fecal metabolic profile was a
direct reflection of changes in microbial composition due to the
antibiotic exposure, it appeared that the antibiotic intervention
impacted fecal metabolites to a greater extent than urinary meta-
bolites, from the number and statistical significance of variables
(altered metabolites) detected. The total number of urinary and
fecal metabolites involved in gut microbialmammalian co-
metabolismdiscovered inour studywas far greater than those reported
so far.10,11,27 These altered metabolites are widely distributed
across the mammalian metabolic system as shown in Supple-
mentary Figure 3 (Supporting Information), many of which are
mammalian metabolites involved in amino acids and glucose
metabolism.
Tryptophan is believed to be associated with gut microbes as it
is metabolized into indole by tryptophanase in intestinal bacteria,
primarily, Escherichia coli,30 which is further absorbed into the
blood from the intestine andmetabolized to indoxyl sulfate in the
liver, and then excreted into urine.With a transient elimination of
most of the gut microbial population, important bacterial en-
zymes such as tryptophanase were rapidly decreased, leading to a
strong perturbation of tryptophan and indole metabolic path-
ways. As a result, indoles were depleted in both urine and feces
while tryptophan levels rose in feces (Figure 4). Tryptamine
significantly increased both in urine and feces presumably due to
the fact that less amount of tryptamine was transformed via micro-
bial enzymes to indole-containing molecules while the produc-
tion of tryptamine via the mammalian metabolic enzyme, tryptho-
phan decarboxylase, remained unaffected. Another metabolite,
6-hydroxymelatonin sulfate, as the major metabolite of melatonin
Figure 4. Dynamic alteration of tryptophanindole metabolism. The bar plots show the fold change (y axis) of each metabolite in the pathway as the
ratio of the concentration in the antibiotic group to that in the control group on days 1, 3, 5, 8 (x axis). The gray bars denote the fecal metabolites, while
the orange bars denote the urinary metabolites.
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and a good marker of melatonin synthesis and secretion,31
increased in urine excretion. Recent studies have shown that
indole modulates expression of proinflammatory genes, increases
expression of anti-inflammatory genes, and strengthens epithelial
cell barrier properties, suggesting that indole is a beneficial
bacterial signal for intestinal epithelial cells.32 In the meantime,
melatonin produced by the pineal gland in the brain and a variety
of peripheral cells such as bone marrow, lymphocytes and
epithelial cells33 was elevated as shown by 6-hydroxymelatonin
elevation both in urine and feces. Since indole and melatonin are
structurally similar to each other and may share certain biological
functions such as antiproliferative properties, the abnormally high
expression of melatonin observed in urine and feces may be directly
associated with the depleted indole level after the gut microbial
disruption for maintaining gut homeostasis. Additionally, several
tryptophan and tyrosine metabolites, as neurotransmitters such as
dopa, dopamine, norepinephrine, and epinephrine, were perturbed
in urine and feces. These findings bring evidence that the
microbialmammalian co-metabolism is strongly associated
with the gut-brain axis (GBA), a bidirectional neurohumoral
communication system that integrates brain and GI functions.34
The GBA seems to regulate homeostasis of GI function, in that
GI motility and epithelial functions determine the habitat of the
microbiota, while changes induced by the central nervous system or
the GI tract alter the habitat and perturb the intestinal microbiota.34
The metabolism of tyrosine and phenylalanine is believed to
be associated with microbiota.27,35 Significant depletion of the
postdose concentrations of hippuric acid (11-fold) and p-cresol
(8 fold) from day 1 to day 5 in the antibiotic group and slight
elevation at the end of the recovery period were observed in
urine. Hippuric acid is a metabolite produced by intestinal
microbes in the presense of quinic acid,27 formed by glycine
conjugation of benzoate. The significant decrease of hippuric
acid was accordance with the observation that Harrison et al.
reported.29 Tyrosine and phenylalanine in feces were noted to be
associated with urinary hippuric acid and phenylacetylglycine
which are produced by the catabolism of these amino acids via
microbiota.35 Hydroxyphenylacetic acid is produced from
tyrosine involving microbial enzymes. That tyrosine altered
only in one day in urine and feces and hydroxyphenylacetic acid
altered almost every day even in the recovery period suggests
that this bacterial-mediated synthesis was greatly impacted
and their recovery was slow. As a result, the concentration
of p-cresol, decarboxylated from p-hydroxyphenylacetic acid,
was also altered.36
SCFAs are monocarboxylic acids with up to six carbon atoms,
such as acetic acid, propionic acid, butyric acid, valeric acid,
2-methylbutyric acid and isovaleric acid. This group of metabo-
lites is probably an important “gateway” between intestinal
bacteria and host metabolism in terms of mtebolic flux and
volume, since SCFAs are primarily generated from the bacterial
fermentation of carbohydrates in the colon, but also serve as
intermediates and precursors of many metabolic activities,
providing energy to muscle, kidney, heart and brain.37 With
antibiotic perturbation, SCFA production by microbiota includ-
ing bacteroidetes, firmicutes, actinobacteria, and proteobacteria is
significantly suppressed.38 SCFAs especially butyric acid was
found depleted in feces in the first several days of the experiment,
and down-regulated in urine until late in the recovery period.
Additionally, free fatty acids, caprylic acid, myristic acid, palmitic
acid, and suberic acid were also found decreased in feces along
with the depleted level of SCFAs.
A number of amino acids, the products of food breakdown and
intermediates of catabolic metabolism with the involvement of
gut microbes, fluctuated as a result of antibiotic exposure. For
example, the histidine level rose and urocanate fell significantly in
feces in the first day of antibiotic treatment as a direct result of
microbial suppression, since histidine is metabolized to urocanic
acid by means of an intestinal enzyme, histidase, produced by
peptostreptococcs asaccharolyticus.39 Histidine and related degraded
products in urine altered to a lesser extent than in feces in the first
day. Urocanic acid altered in the same direction in urine but with
a lower fold change compared to that in feces.
Several oligopeptides especially dipeptides and tripeptides
were found elevated in urine of the antibiotic group, presumably
due to the high expression of H+/peptide transporter PepT1,
leading to the increased small peptides excretion through kidney
as a result of transient gut microbial disruption. An important
transport function expressed by gut epithelial cells is the absorp-
tion of small peptides from the diet by an apical membrane
peptide transporter.40 Intestinal adaptation after inflammation is
characterized by increased gut-mucosal growth, as reported that
the H+/peptide transporter PepT1 expression was high in the
colonic mucosa of patients with short-bowel syndrome (SBS), so
that the large intestine has a mechanism for luminal di- and tri-
peptide transport, increasing the absorption of di- and tripep-
tides.41 Therefore, rapidly increased levels of dipeptides and
tripeptides may be potential markers for intestinal dysbiosis.
Urobilin was also significantly down-regulated both in urine
and feces. Urobilin, the degradation product of bilirubin, is one of
the most important compounds of urobilinoids formed in the Gl
tract by intestinal microbes. With antibiotic suppressed bilirubin-
degradation microbes, urobilinoids were lowered significantly
as our results show. Urobilin was also down-regulated in urine,
however not as significantly as in feces, due to the fact that
urobilinoids underwent enterohepatic and enterosystemic
circulation and only about 1020% were reabsorbed and
excreted in urine.42
The present methodological study aimed to investigate the
feasibility of metabonomic profiling approach to capture a full
spectrum of metabolic changes derived from gut microbialhost
co-metabolism. The results of the study suggest that metagenomic
compositional changes can be eventually monitored and probed
using a metabonomic approach, providing that the two sets of
changes can be correlated to each other.
’CONCLUSION
Real time analysis of the small molecule metabolites derived
from microbialmammalian metabolic cooperation is essential
for the understanding of the metabolic functions of the meta-
genome with tremendous implications for personalized health-
care strategies. The study identified a panel of urinary and fecal
metabolites involved in gut microbialmammalian co-metabo-
lism using a combined GCMS and LCMS metabonomic
profiling approach. This study also brings further evidence that
the gut microbiota modulate the host systemic metabolism
involving tryptophan, lipids, amino acids, and possibly a com-
pensatory mechanism of indole-melatonin production. It ap-
peared that the recovery of the global metabonomic changes
takes about two-weeks. With the use of complementary LCMS
and GCMS platforms,∼800 endogenous metabolite standards
andotherweb-basedmetabolite databases in this study, we identified
a panel of 202 urinary and 223 fecal metabolites (p < 0.05 in at
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least one day) significantly altered as a readout of a gut micro-
bialmammalian co-metabolism, many of which have not been
previously reported.
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